Skye Bioscience Investor Day on CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System
About The Event
Join Skye Bioscience for a virtual Investor Day featuring Brian Levy, O.D. (former CMO, Aerie and Bausch & Lomb), Glenwood Gum, Ph.D. (Pharmaron), and Sameh Mosaed, M.D., Ph.D. (UC Irvine), who will provide an overview of the current glaucoma commercial landscape, drug development pipeline, and perspective on the historical challenges to achieving CB1-targeting therapeutics for the treatment of glaucoma.
Skye leadership will provide broad insight into SBI-100 Ophthalmic Emulsion, its CB1 agonist being developed to potentially treat glaucoma, including a nonclinical data overview, clinical data from the company’s recently completed Phase 1 study, a Phase 2 clinical update, and an outline of the glaucoma market opportunity and Skye’s positioning strategy.
A live question and answer session will follow the formal presentations.